Compare Smith & Nephew plc (SNN) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Virgin Galactic Holdings, Inc. — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.31B), while Virgin Galactic Holdings, Inc. trades at $2.95 (market cap $456.30M). The key difference: Smith & Nephew plc is far larger — about 24.8× Virgin Galactic Holdings, Inc.'s market cap, and Smith & Nephew plc pays a 2.95% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| SNN | SPCE | |
|---|---|---|
Market Cap | $11.31B | $456.30M |
Volume | 1,050,005 | 4,518,834 |
Sector | Health | Industrials |
52-Week High | $37.17 | $7.52 |
52-Week Low | $26.42 | $2.17 |
Typical Hold Time | 120 Days | 69 Days |
Enterprise Value | $14.35B | $420.29M |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting persistent operational losses and a bearish technical outlook. The company continues to burn cash with negative gross and net profit margins, though recent earnings beats and strong ticket demand for future spaceflights offer a glimmer of hope. Cash flow trends show a gradual improvement, with a projected positive net cash flow of $25 million in 2026.
The outlook remains high-risk, high-reward. The path to profitability hinges on the successful commercial launch of Delta flights in 2027. While analyst sentiment is mixed and significant dilution and debt are concerns, the company's unique position in commercial spaceflight presents a speculative opportunity for investors with a long-term horizon and high risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
